Compare Stocks: STTK, BHVN, AUPH, and AGIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.03 +3.2%	$33.57	$22.24 ▼ $46.00	N/A	N/A	N/A	739,079 shs
AUPH Aurinia Pharmaceuticals	$17.25 +1.2%	$16.44	$11.96 ▼ $19.25	N/A	N/A	N/A	494,477 shs
BHVN Biohaven	$15.28 +5.7%	$13.51	$7.48 ▼ $18.57	N/A	N/A	N/A	2.43 million shs
STTK Shattuck Labs	$5.77 +4.2%	$6.39	$1.72 ▼ $8.33	N/A	N/A	N/A	699,500 shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-0.41%	+5.59%	+13.11%	+2.39%	-14.95%
AUPH Aurinia Pharmaceuticals	+1.07%	+3.34%	+3.65%	+13.90%	+43.31%
BHVN Biohaven	+4.11%	+27.27%	+11.46%	+5.10%	-12.86%
STTK Shattuck Labs	+0.91%	+3.17%	-8.73%	-18.77%	+188.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.03 +3.2%	$33.57	$22.24 ▼ $46.00	N/A	N/A	N/A	739,079 shs
AUPH Aurinia Pharmaceuticals	$17.25 +1.2%	$16.44	$11.96 ▼ $19.25	N/A	N/A	N/A	494,477 shs
BHVN Biohaven	$15.28 +5.7%	$13.51	$7.48 ▼ $18.57	N/A	N/A	N/A	2.43 million shs
STTK Shattuck Labs	$5.77 +4.2%	$6.39	$1.72 ▼ $8.33	N/A	N/A	N/A	699,500 shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-0.41%	+5.59%	+13.11%	+2.39%	-14.95%
AUPH Aurinia Pharmaceuticals	+1.07%	+3.34%	+3.65%	+13.90%	+43.31%
BHVN Biohaven	+4.11%	+27.27%	+11.46%	+5.10%	-12.86%
STTK Shattuck Labs	+0.91%	+3.17%	-8.73%	-18.77%	+188.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.50	9.12% Upside
AUPH Aurinia Pharmaceuticals	2.71	Moderate Buy	$17.75	2.90% Upside
BHVN Biohaven	2.59	Moderate Buy	$19.25	25.98% Upside
STTK Shattuck Labs	3.08	Buy	$13.70	137.44% Upside

Current Analyst Ratings Breakdown

Latest STTK, BHVN, AUPH, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Sector Perform	$19.00 ➝ $22.00
10/22/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)
10/22/2026	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$48.00
10/21/2026	AUPH Aurinia Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$17.00 ➝ $18.00
10/11/2026	STTK Shattuck Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$17.00
10/11/2026	STTK Shattuck Labs	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/8/2026	BHVN Biohaven	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy
10/7/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$39.00 ➝ $37.00
10/2/2026	STTK Shattuck Labs	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$11.00 ➝ $14.00
10/2/2026	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$17.00 ➝ $19.00
9/21/2026	AGIO Agios Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	N/A	-$7.01	N/A	N/A	N/A	N/A	N/A	N/A	11/5/2026 (Estimated)
AUPH Aurinia Pharmaceuticals	N/A	$2.29	N/A	16.43	N/A	N/A	N/A	N/A	11/3/2026 (Estimated)
BHVN Biohaven	N/A	-$4.64	N/A	N/A	N/A	N/A	N/A	N/A	11/9/2026 (Estimated)
STTK Shattuck Labs	N/A	-$0.51	N/A	N/A	N/A	N/A	N/A	N/A	11/10/2026 (Estimated)

Latest STTK, BHVN, AUPH, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/10/2026	Q3 2026	STTK Shattuck Labs	-$0.10	N/A	N/A	N/A	$0.03 million	N/A
11/9/2026	Q3 2026	BHVN Biohaven	-$0.7833	N/A	N/A	N/A	$63.64 million	N/A
11/5/2026	Q3 2026	AGIO Agios Pharmaceuticals	-$1.25	N/A	N/A	N/A	$51.55 million	N/A
11/3/2026	Q3 2026	AUPH Aurinia Pharmaceuticals	$0.22	N/A	N/A	N/A	$83.61 million	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
AUPH Aurinia Pharmaceuticals	36.83%
BHVN Biohaven	88.78%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
AUPH Aurinia Pharmaceuticals	10.40%
BHVN Biohaven	13.80%
STTK Shattuck Labs	8.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	540	N/A	56.48 million	Optionable
AUPH Aurinia Pharmaceuticals	128	N/A	119.21 million	Optionable
BHVN Biohaven	274	N/A	130.20 million	Optionable
STTK Shattuck Labs	40	N/A	91.54 million	Optionable

STTK, BHVN, AUPH, and AGIO Headlines

Recent News About These Companies

Shattuck Labs, Inc. (NASDAQ:STTK) Stock Has Average Target Price of $13.70 According to Brokerages

October 25 at 2:45 AM | americanbankingnews.com

Piper Sandler Remains a Buy on Shattuck Labs (STTK)

October 22, 2026 | theglobeandmail.com

Shattuck Labs, Inc. $STTK Stock Purchased by Pinnacle Associates Ltd.

October 22, 2026 | marketbeat.com

Critical Survey: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Shattuck Labs (NASDAQ:STTK)

October 22, 2026 | americanbankingnews.com

Shattuck Labs, Inc. (NASDAQ:STTK) Stock Has Consensus Price Target of $13.70

October 20, 2026 | marketbeat.com

Shattuck Labs, Inc. (NASDAQ:STTK) Sees Large Growth in Short Interest

October 16, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Upgraded at UBS Group

October 14, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Falls 6.9% - Time to Sell?

October 13, 2026 | marketbeat.com

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

October 13, 2026 | globenewswire.com

UBS Initiates Shattuck Labs at Buy With $17 Price Target

October 12, 2026 | marketscreener.comM

Shattuck Labs (STTK) Receives a Buy from Leerink Partners

October 5, 2026 | theglobeandmail.com

Shattuck Labs (NASDAQ:STTK) Stock Price Down 5.3% - What's Next?

October 5, 2026 | marketbeat.com

Shattuck Labs (NASDAQ:STTK) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

October 2, 2026 | marketbeat.com

Shattuck Labs Plans Phase 2 Trial of Chronic Inflammatory Skin Disease Drug

October 1, 2026 | finance.yahoo.com

Shattuck Advances SL-325 Into Phase 2 Hidradenitis Suppurativa Trial

October 1, 2026 | rttnews.com

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

October 1, 2026 | globenewswire.com

Shattuck Labs (NASDAQ:STTK) Shares Up 11.9% - Time to Buy?

September 30, 2026 | marketbeat.com

Shattuck Labs, Inc.(NasdaqGS:STTK) added to S&P Biotechnology Select Industry Index

September 21, 2026 | marketscreener.comM

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

September 2, 2026 | globenewswire.com

Shattuck Labs: A Receptor-Side Bet On The TL1A Boom

September 1, 2026 | seekingalpha.com

Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?

August 20, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, BHVN, AUPH, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.03 +1.18 (+3.20%)

Closing price 04:00 PM Eastern

Extended Trading

$38.01 -0.02 (-0.05%)

As of 07:30 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Aurinia Pharmaceuticals NASDAQ:AUPH

$17.25 +0.21 (+1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$17.26 +0.01 (+0.06%)

As of 07:30 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Biohaven NYSE:BHVN

$15.28 +0.83 (+5.74%)

Closing price 03:59 PM Eastern

Extended Trading

$15.12 -0.16 (-1.02%)

As of 07:58 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Shattuck Labs NASDAQ:STTK

$5.77 +0.23 (+4.15%)

Closing price 04:00 PM Eastern

Extended Trading

$5.77 0.00 (0.00%)

As of 07:30 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, BHVN, AUPH, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, BHVN, AUPH, and AGIO Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, BHVN, AUPH, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, BHVN, AUPH, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Aurinia Pharmaceuticals NASDAQ:AUPH

Biohaven NYSE:BHVN

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STTK, BHVN, AUPH, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STTK, BHVN, AUPH, and AGIO Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STTK, BHVN, AUPH, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK, BHVN, AUPH, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Aurinia Pharmaceuticals NASDAQ:AUPH

Biohaven NYSE:BHVN

Shattuck Labs NASDAQ:STTK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools